How should candiduria be managed, including when to treat and which antifungal regimen to use?

Management of Candiduria (Yeast in Urine)

Most patients with candiduria should NOT receive antifungal treatment—the priority is removing urinary catheters and eliminating predisposing factors, reserving antifungal therapy only for high-risk groups or symptomatic infections. 1

When NOT to Treat: Asymptomatic Candiduria

The vast majority of candiduria cases are asymptomatic colonization and do not require antifungal therapy. 1, 2

Key principle: Asymptomatic candiduria does not warrant treatment in most patients, as antifungal therapy does not improve mortality, reduce recurrence, or shorten hospital stays. 1, 3

Management of Asymptomatic Patients:

• Remove or replace indwelling urinary catheters immediately—this is the single most critical intervention and often resolves candiduria without medication. 1, 2

• Discontinue broad-spectrum antibiotics when feasible, as they are a major predisposing factor. 4

• Do NOT start empirical antifungal therapy in asymptomatic patients—studies show 43-93% of asymptomatic candiduria is inappropriately overtreated, contributing to antifungal resistance without clinical benefit. 5, 3

• Observe clinically for 1-2 weeks after catheter removal; most cases resolve spontaneously. 2

When TO Treat: High-Risk Groups

Antifungal treatment is indicated ONLY for specific high-risk populations, even when asymptomatic: 1, 2

Three High-Risk Groups Requiring Treatment:

1. Neutropenic patients (treat as candidemia with systemic therapy) 1, 4

2. Very low-birth-weight infants (<1500 g) (treat as candidemia) 1, 4

3. Patients undergoing urologic procedures (prophylaxis required) 1, 2, 4

Prophylaxis for Urologic Procedures:

• Fluconazole 400 mg (6 mg/kg) daily OR amphotericin B deoxycholate 0.3-0.6 mg/kg daily starting several days before the procedure and continuing several days after. 1, 2

When TO Treat: Symptomatic Infections

Antifungal therapy is indicated when candiduria causes symptomatic urinary tract infection. 1, 4

Candida Cystitis (Lower Urinary Tract):

For fluconazole-susceptible species (most C. albicans):

• Fluconazole 200 mg (3 mg/kg) PO daily for 14 days 1, 2
• Remove indwelling catheter if present 1

For fluconazole-resistant C. glabrata:

• Amphotericin B deoxycholate 0.3-0.6 mg/kg IV daily for 1-7 days OR flucytosine 25 mg/kg PO four times daily for 7-10 days 1, 2
• Amphotericin B bladder irrigation (50 mg/L sterile water daily for 5 days) may be considered as adjunctive therapy 1

For C. krusei:

• Amphotericin B deoxycholate 0.3-0.6 mg/kg IV daily for 1-7 days 1

Candida Pyelonephritis (Upper Urinary Tract):

For fluconazole-susceptible species:

• Fluconazole 200-400 mg (3-6 mg/kg) PO daily for 14 days 1, 2
• Higher doses (400 mg) recommended for more severe infections 2

For fluconazole-resistant C. glabrata:

• Amphotericin B deoxycholate 0.3-0.6 mg/kg IV daily for 1-7 days with or without flucytosine 25 mg/kg PO four times daily 1, 2
• Flucytosine monotherapy (25 mg/kg four times daily for 14 days) can be considered when amphotericin B is contraindicated 1, 2

For C. krusei:

• Amphotericin B deoxycholate 0.3-0.6 mg/kg IV daily for 1-7 days 1

Additional Interventions for Pyelonephritis:

• Eliminate urinary tract obstruction (critical for treatment success) 1
• Remove or replace nephrostomy tubes/stents when feasible 1

Critical Diagnostic Steps

Always obtain urine culture with species identification and antifungal susceptibility testing BEFORE initiating therapy—fluconazole susceptibility varies widely among Candida species, and empirical treatment often leads to inappropriate drug selection. 2, 6

Species-Specific Considerations:

• C. albicans (most common): Usually fluconazole-susceptible 5, 6
• C. glabrata (second most common): Often fluconazole-resistant, requiring amphotericin B or flucytosine 1, 6
• C. krusei: Intrinsically fluconazole-resistant, always requires amphotericin B 1
• C. tropicalis: Usually fluconazole-susceptible but resistance emerging 6

Common Pitfalls to Avoid

Overtreatment of Asymptomatic Candiduria:

Studies demonstrate that 43-80% of asymptomatic candiduria cases are inappropriately treated with antifungals, despite clear guideline recommendations against this practice. 5, 3 This overtreatment:

• Does not reduce mortality or recurrence 3, 7
• May increase 30-day readmission rates 3
• Promotes antifungal resistance 5, 6
• Increases healthcare costs without clinical benefit 5

Inappropriate Drug Selection:

• Echinocandins (micafungin, caspofungin, anidulafungin) do NOT achieve adequate urinary concentrations and should not be used for urinary tract candidiasis 4
• Fluconazole is the only azole that achieves high urinary levels—other azoles (itraconazole, voriconazole, posaconazole) are inadequate for urinary infections 4
• Fluconazole therapeutic failure occurs in up to 37% of symptomatic cases, often due to resistant species or inadequate dosing 6

Failure to Remove Catheters:

Indwelling urinary catheters are the principal predisposing factor for candiduria, and failure to remove them is associated with higher mortality and treatment failure. 2, 7 Catheter removal reduces mortality more effectively than antifungal therapy alone. 7

Special Populations

Renal Transplant Recipients:

• Asymptomatic candiduria with bladder leukoplakia does NOT require antifungal treatment 2
• Remove JJ stents immediately 2
• Treat only if symptomatic infection develops (fever, flank pain, declining graft function) 2
• Azole antifungals markedly increase tacrolimus levels via CYP3A4 inhibition—reduce tacrolimus dose by 50-75% and monitor levels every 2-3 days when starting fluconazole 2
• Amphotericin B does not interact with tacrolimus but has additive nephrotoxicity requiring close renal function monitoring 2

ICU Patients:

Candiduria is common in critically ill patients (7.8% incidence in one study), with high mortality (25-30%) regardless of treatment. 6 The mortality is driven by underlying illness severity rather than candiduria itself, reinforcing that asymptomatic candiduria should not be treated. 6, 7

Management Algorithm

1. Identify candiduria on urine culture → Obtain species identification and susceptibility testing 2, 6

2. Assess for symptoms:

   • Fever, dysuria, flank pain, suprapubic pain, or declining renal function?
   • If NO → Asymptomatic candiduria

3. For asymptomatic candiduria:

   • Check if patient is neutropenic, very low-birth-weight infant, or scheduled for urologic procedure
   • If YES → Treat per high-risk protocol 1, 2
   • If NO → Remove catheter, discontinue antibiotics, observe clinically 1, 2, 7

4. For symptomatic candiduria:

   • Remove catheter and eliminate obstruction 1
   • Start fluconazole 200-400 mg daily for 14 days if susceptible species 1, 2
   • Use amphotericin B 0.3-0.6 mg/kg daily if resistant species (C. glabrata, C. krusei) 1, 2

5. Monitor response:

   • Repeat urine culture 1-2 weeks after treatment completion 7
   • If recurrence occurs, reassess for retained catheters or anatomic abnormalities 3